Is the global equity rally broadening? UBS weighs in

UBS expects global equities to continue advancing after a June/July pause, forecasting earnings growth of 26% in 2025 and 14% in 2026. The bank cites a constructive macro backdrop—expansionary fiscal policy and manufacturing PMIs back in expansion territory—while expecting inflation to ease as tariff headwinds recede and viewing a sustained rate-hike cycle as unlikely. UBS also expects valuation normalization (MSCI AC World forward P/E ~15% below its November peak) and has upgraded European tech and Taiwan, though it flags risks from Strait of Hormuz reopening timing and rising yields.

Analysis

The actionable read is not "buy megacap tech" but "own the catch-up trade": if earnings breadth is improving while valuations have largely mean-reverted, the next leg should favor cyclicals, financials, and active managers over the same crowded AI leaders. That setup is especially relevant for MSCI, which benefits if institutional and ETF flows broaden beyond a narrow growth basket, and for C if capital markets activity and credit quality stay stable enough to support a more diversified revenue mix.

The main near-term risk is that the market is pricing a benign glide path while the macro is still vulnerable to yield spikes and geopolitics. Rising real yields are the cleanest threat to the broadening thesis because they can compress multiple expansion faster than analysts can lift numbers; that would hit global beta vehicles first and only later show up in earnings revisions. Conversely, if PMIs stay in expansion and inflation continues easing, the next 1-3 months should favor cyclically exposed financials and Europe/Asia equities rather than U.S. duration-heavy growth.

The contrarian point is that a lot of the good news is already visible in the index-level valuation reset, so the upside may come more from relative performance than absolute index gains. The consensus may be underweighting how quickly a risk-off shock from the Strait of Hormuz or a sudden yield break can unwind a breadth trade. For a 6-18 month horizon, the real determinant is whether AI capex monetization stays incremental; if not, the market will rotate from "growth at any price" into balance-sheet strength and cash return, which is where the next winners should emerge.

Key Decisions for Investors

• Long MSCI vs short a U.S. mega-cap tech proxy for a 1-3 month breadth rotation: if earnings breadth is real, MSCI should benefit from rising AUM and passive inflows while crowded growth names remain vulnerable to multiple compression; stop if 10Y real yields break materially higher.
• Initiate a small long in C on any market pullback over the next 1-2 weeks: Citi has more operating leverage to a broadening capital-markets cycle than to index-level tech momentum, with upside if credit remains benign; thesis fails if trading revenue and loan-loss guidance deteriorate next quarter.
• Buy global cyclical exposure through WWRL only on weakness, not strength: use it as a beta expression for a 3-6 month broadening trade, but reduce if oil or rates spike and the ETF cannot hold recent relative lows.
• Pair long European or Asia cyclicals against U.S. long-duration growth if you need a cleaner expression of the UBS thesis: the relative-value trade should work best over 1-3 months if PMIs and fiscal support keep improving; exit if tariff/inflation data re-accelerate.
• Set a watchlist trigger on 10Y real yields and Brent: a sustained move higher would be the first falsifier of the 'buy the dip' setup, arguing for de-risking index beta and rotating into cash-generative defensives.